SARS-CoV-2 IgG Antibody Response after Immunization of Healthcare Workers with Inactivated COVID-19 Vaccine (CoronaVac) at Phyathai 3 Hospital
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To evaluate the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) anti-spike Immunoglobulin G (IgG) antibody response after CoronoVac immunization of healthcare workers at Phyathai 3 Hospital.
MATERIALS AND METHODS: The descriptive study was performed at Phyathai 3 Hospital between March 2021 and May 2021. Healthcare workers who received two doses (three weeks apart) of the CoronaVac vaccine were included. Blood samples for anti-spike IgG antibodies were taken from each healthcare worker before getting vaccinated and four weeks after completing two doses of the vaccine.
RESULT: A total of 88 healthcare workers were enrolled in our study. Fifty-three (60%) of them were female, 84(95%) were physicians, 46(52%) were obese and 33(37.5%) had at least one coexisting condition. The mean age was 45.8 ± 9.3 years. Seven (8%) of participants were older than 60 years of age. All participants did not have IgG antibodies at baseline. Eighty-seven (98.9%) healthcare workers had seroconversion of anti-spike IgG antibodies four weeks after completing two doses of the CoronaVac vaccine. The mean level of anti-spike IgG at four weeks after completing vaccination was 115+/-85 unit/ml (range, 1.77-297.3 unit/ml). Anti-spike IgG levels were significantly higher in females than males (p = 0.02). Normal-weight participants showed higher anti-spike IgG levels than obese individuals (p = 0.01). IgG antibody responses tended to decrease with age. The highest IgG levels were observed in the ages of 30-40 years. CONCLUSION: Two doses of the CoronaVac vaccine could induce a 98.9% rate of seroconversion in healthcare workers. Female and normal-weight participants were significantly associated with a higher level of IgG response. Younger adults had a higher immune response than older adults in our setting.
Article Details
This article is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may copy and redistribute the material for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Modified versions may not be distributed under this license.
License: https://creativecommons.org/licenses/by-nc-nd/4.0/
References
World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. (Accessed on May 14, 2021, at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance ).
Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. 2019. (Accessed on May 14, 2021, at https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html ).
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497.
Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med 2021;174:69.
World Health Organization. Transmission of SARS-CoV-2: Implications for infection prevention precautions. (Accessed on May 14, 2021, at https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations ).
Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating COVID-19. Infect Control Hosp Epidemiol 2020;41(9):1064-5.
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181-92.
Sinovac. Sinovac Announces Phase III Results of its COVID-19 Vaccine. (Accessed on February 5, 2021, at http://www.sinovac.com/?optionid=754&auto_id=922b ).
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020: 586(7830):589-93.
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—Preliminary report. N Engl J Med 2020; 383:1920-31.
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396:
–78.
